Publication at First Faculty of Medicine |
2015
Abstract
Prostatic carcinoma is one of the most frequent malignant disease in man. Majority of complications and near all mortality is associated with metastatic and castration-resistant phase of prostate cancer (mCPRC).
Except chemotherapy and targeted external radiotherapy it is possible to administer bone seeking beta or alpha emitters. In this short review authors present the possibilities and advantages of this therapy and its indications and contraindications.